HawkCell develops proprietary magnetic resonance imaging (MRI) technology for veterinary care and preclinical research. Its core product is a patented system that integrates advanced hardware and software to deliver rapid, accurate, and quantitative analyses for veterinarians and for the in vivo assessment of drug candidates and medical devices. The company says the technology supports an extensive range of fields including neurology, cardiology, gastrointestinal and musculoskeletal disorders, inflammation, oncology, metabolic diseases, and biocompatibility evaluations. HawkCell plans to use new funding to scale up its business and to enhance its ongoing efforts to elevate animal imaging. The company is also driving expansion into the North American pet market. The business is led by CEO Alexis Girin and is based in Lyon, France.

Total raised

$5M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2024